Table 3.
Summary of Sensitivity Analyses
| Predictor | Outcome | No. of Models |
No. (%) of Converged Models P < .05 (P < .1) |
|||
|---|---|---|---|---|---|---|
| Tested | Converged | Asymptote | Y0 | LRC | ||
| CMV intercept | CD4 | 6 | 4 | 0 | 0 | 50 (75) |
| CD8 | 6 | 5 | 60 (80) | 0 | 0 | |
| CD4/CD8 | 6 | 6 | 67 (83) | 67 (100) | 33 (50) | |
| EBV intercept | CD4 | 6 | 0 | NA | NA | NA |
| CD8 | 6 | 5 | 0 (80) | 80 (80) | 40 (80) | |
| CD4/CD8 | 6 | 6 | 0 | 67 (83) | 0 | |
| Age | CD4 | 4 | 2 | 0 | 0 | 0 |
| CD8 | 4 | 4 | 0 | 0 | 0 | |
| CD4/CD8 | 4 | 4 | 100 (100) | 25 (50) | 0 (25) | |
| Peak viral load (log) | CD4 | 4 | 3 | 0 | 0 | 0 |
| CD8 | 4 | 3 | 0 | 100 (100) | 33 (33) | |
| CD4/CD8 | 4 | 4 | 0 | 25 (75) | 0 | |
| Timing of ART in month (log + 1) | CD4 | 4 | 1 | 0 | 0 (100) | 0 |
| CD8 | 4 | 3 | 0 | 67 (100) | 67 (100) | |
| CD4/CD8 | 4 | 4 | 0 | 0 | 0 | |
Abbreviations: ART, antiretroviral therapy; CMV, cytomegalovirus; EBV, Epstein-Barr virus; LRC, natural logarithm of the rate constant; NA, not available; Y0, baseline.